Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children17110.24287/1726-1708-2018-17-2-9-20PROMISING STUDIESПЕРСПЕКТИВНЫЕ ИССЛЕДОВАНИЯLow dose donor memory T-cell infusion after TCR alpha/beta depleted stem cell transplantation for patients with malignant disordersПрименение инфузий T-клеток памяти с целью профилактики вирусных инфекций у пациентов с гемобластозами, перенесших аллогенную трансплантацию гемопоэтических стволовых клеток с деплецией альфа/бета-Т-лимфоцитовhttps://orcid.org/0000-0001-8754-1376BlagovS. L.БлаговС. Л.
Russian Federation

MD, Department of optimization treatment and prevention of complications of hematopoietic stem cell transplantation

Russia 117997, Moscow, Samory Mashela st., 1

врач-гематолог отделения ТГСК №1

117997, Москва, ГСП-7, ул. Саморы Машела, 1

sblagov89@gmail.comhttps://orcid.org/0000-0003-0520-5630ShelikhovaL. N.ШелиховаЛ. Н.https://orcid.org/0000-0002-1873-3486OsipovaE. Y.ОсиповаЕ. Ю.https://orcid.org/0000-0002-3001-4820KiselevaV. V.КиселеваВ. В.https://orcid.org/0000-0003-0497-9175KazachenokA. S.КазаченокА. С.https://orcid.org/0000-0002-9912-6572ShekhovtsovaZ. B.ШеховцоваЖ. Б.https://orcid.org/0000-0002-9282-6883BogoyavlenskayaA. A.БогоявленскаяА. А.https://orcid.org/0000-0003-4911-0553NovichkovaG. A.НовичковаГ. А.https://orcid.org/0000-0002-0016-6698MaschanA. A.МасчанА. А.https://orcid.org/0000-0003-1735-0093MaschanM. A.МасчанМ. А.Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, ImmunologyФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева»2009201817292020092018Copyright ©; 1970, «D. Rogachev NMRCPHOI»Copyright ©; 1970, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России1970«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/171

Viral infections are frequent complications in the recipients of the HSCT with TCRαβ and CD19-graft depletion. Adoptive transfer of memory T cells may improve immune response to common pathogens. The work reflects the retrospective safety analysis of using the infusions of CD45RA-depleted donor lymphocytes. Data from 80 patients were analyzed. Up to 3 doses of donor lymphocytes were administered at monthly intervals, escalating to 100 × 103/kg in haploidentical transplants and 300 × 103/kg in MUD transplants. Median follow-up for alive patients was 18 (8–44) months. We did not observe any allergic reactions, septic complications after infusion of donor lymphocytes (DLI). The cumulative incidence of a de novo acute GVHD after DLI was 5% (95% CI: 2–13). In 64% patients (n = 51) was detected CMV in the blood. There were no cases of resistant CMV disease on the background of drug therapy. In patients who received DLI, 70% (n = 56) had documented appearance of virus-specific lymphocytes in peripheral blood (Elispot assay). Thus, the introduction of memory T cells at a dose of 25–100 × 103/kg body weight of the recipient for CD3+ in the case of HSCT from a haploidentical donor and 100–300 × 103/kg for an unrelated HSCT. Infusions of low dose memory T-lymphocytes after transplant engraftment are safe, potentially effective and constitute a simple measure to prevent infections in the setting of alpha/beta T-cell-depleted transplantation.

memory T-cellsgraft TCRαβ depletionallogeneic HSCTТ-клетки памятиTCRальфа-бета-деплецияаллогенная ТГСКChaleff S., Otto M., Barfield R.C., Leimig T., Iyengar R., Martin J., et al. A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy 2007; 9 (8): 746-54.Handgretinger R. Negative depletion of CD3(+) and TcRalphabeta(+) T-cells. Curr Opin Hematol 2012; 19 (6): 434-9.Schumm M., Lang P., Bethge W., Faul C., Feuchtinger T., Pfeiffer M., et al. Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy 2013; 15 (10): 1253-8.Bertaina A., Merli P., Rutella S., Pagliara D., Bernardo M.E., Masetti R., et al. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant disorders. Blood 2014; 124 (5): 822-6.Balashov D., Shcherbina A., Maschan M., Trakhtman P., Skvortsova Y., Shelikho-va L., et al. Single-Center Experience of Unrelated and Haploidentical Stem Cell Transplantation with TCRalphabeta and CD19 Depletion in Children with Primary Immunodeficiency Syndromes. Biol Blood Marrow Transplant 2015; 21 (11): 1955-62.Maschan M., Shelikhova L., Ilushina M., Kurnikova E., Boyakova E., Balashov D., et al. TCR-alpha/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia. Bone Marrow Transplant 2016; 51 (5): 668-74.Zvyagin I.V., Mamedov I.Z., Tatarinova O.V., Komech E.A., Kurnikova E.E., Boyakova E.V., et al. Tracking T-cell immune reconstitution after TCRalphabeta/CD19-depleted hemato-poietic cells transplantation in children. Leukemia 2016; 31: 1145-53.Airoldi I., Bertaina A., Prigione I., Zorzoli A., Pagliara D., Cocco C., et al. gammadelta T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-alphabeta+/CD19+ lymphocytes. Blood 2015; 125: 2349-58.Богоявленская А.А., Лаберко А.Л., Шелихова Л.Н., Шеховцова Ж.Б., Балашов Д.Н., Воронин К.А. идр. Герпес-вирусные инфекции у реципиентов аллогенной трансплантации гемопоэтических стволовых клеток с TCRаьфа-бета и CD19-деплецией: факторы риска и прогноз. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2017; 16 (1): 10-21.Laberko A., Bogoyavlenskaya A., Sheli-khova L., Shekhovtsova Z., Balashov D., Voronin K., et al. Risk Factors for and the Clinical Impact of Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Recipients of TCR-alpha/beta- and CD19-Depleted Grafts. Biol Blood Marrow Transplant 2016; 23: 489-90.Heslop H.E., Ng C.Y., Li C., Smith C.A., Loftin S.K., Krance R.A., et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2 (5): 551-5.Papadopoulou A., Gerdemann U., Katari U.L., Tzannou I., Liu H., Martinez C., et al. Activity of broad-spectrum T-cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 2014; 6 (242): 242-83.Peggs K.S., Verfuerth S., Pizzey A., Khan N., Guiver M., Moss P.A., et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362 (9393): 1375-7.Schmitt A., Tonn T., Busch D.H., Grigoleit G.U., Einsele H., Odendahl M., et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T-cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011; 51 (3): 591-9.Bleakley M., Heimfeld S., Loeb K.R., Jones L.A., Chaney C., Seropian S., et al. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Invest 2015; 125 (7): 2677-89.Shook D.R., Triplett B.M., Eldridge P.W., Kang G., Srinivasan A., Leung W. Haploidentical stem cell transplantation augmented by CD45RA negative lymphocytes provides rapid engraftment and excellent tolerability. Pediatr Blood Cancer 2015; 62 (4): 666-73.Teschner D., Distler E., Wehler D., Frey M., Marandiuc D., Langeveld K., et al. Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis. Bone Marrow Transplant 2014; 49 (1): 138-44.Touzot F., Neven B., Dal-Cortivo L., Gabrion A., Moshous D., Cros G., et al. CD45RA depletion in HLA-mismatched allogeneic hematopoietic stem cell transplantation for primary combined immunodeficiency: A preliminary study. J Allergy Clin Immunol 2015; 135( 5): 1303-19 e1301-3.Bleakley M., Heimfeld S., Jones L.A., Turtle C., Krause D., Riddell S.R., et al. Engineering human peripheral blood stem cell grafts that are depleted of naive T-cells and retain functional pathogen-specific memory T cells. Biol Blood Marrow Transplant 2014; 20 (5): 705-16.Brodszki N., Turkiewicz D., Toporski J., Truedsson L., Dykes J. Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions. Orphanet J Rare Dis 2016; 11: 5.Przepiorka D., Weisdorf D., Martin P., Klingemann H.G., Beatty P., Hows J., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15 (6): 825-8.Melenhorst J.J., Leen A.M., Bollard C.M., Quigley M.F., Price D.A., Rooney C.M., et al. Allogeneic virus-specific T-cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 2010; 116 (22): 4700-2.Melenhorst J.J., Scheinberg P., Willi-ams A., Ambrozak D.R., Keyvanfar K., Smith M., et al. Alloreactivity across HLA barriers is mediated by both naive and antigen-experienced T cells. Biol Blood Marrow Transplant 2011; 17 (6): 800-9.D'Orsogna L.J., Roelen D.L., Doxiadis I.I., Claas F.H. Alloreactivity from human viral specific memory T-cells. Transpl Immunol 2010; 23 (4): 149-55.D'Orsogna L.J., van der Meer-Prins E.M., Zoet Y.M., Roelen D.L., Doxiadis I.I., Claas F.H.. Detection of allo-HLA cross-reactivity by virus-specific memory T-cell clones using single HLA-transfected K562 cells. Methods Mol Biol 2012; 882: 339-49.Triplett B.M., Shook D.R., Eldridge P., Li Y., Kang G., Dallas M., et al. Rapid memory T-cell reconstitution recapitulating CD45RA-depleted haploidentical transplant graft content in patients with hematologic malignancies. Bone Marrow Transplant 2015; 50 (7): 968-77.Jain N.A., Lu K., Ito S., Muranski P., Hourigan C.S., Haggerty J., et al. The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches. Cytotherapy 2014; 16 (7): 927-33.